Larger prospective studies will be necessary to determine the effectiveness of PTCy in combination with other drugs in preventing GVHD, as well as the optimal interval between the last dose of PD-1 inhibitor administration and allo-HCT in order to minimize the occurrence of severe immune-related complications (58). The gene discussed is PDCD1; the disease is graft versus host disease.